December 02, 2015 –  The American Food and Drug Administration (FDA) just granted approval for Elotuzumab (Empliciti) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Elotuzumab (Empliciti) is a monoclonal …

Elotuzumab (Empliciti), a new immune-stimulating therapy to treat multiple myeloma has been approved Read more »